Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

HIV Clinical Trial

Official title:

Maintenance of Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir in Virologically Suppressed HIV-infected Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03727152
• Other study ID #: HIV-NAT 256
• Status: Completed
• Phase: Phase 3
• Start date: May 1, 2019
• Est. completion date: April 4, 2023

Study information

• Verified date: February 2024
• Source: The HIV Netherlands Australia Thailand Research Collaboration
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults

Description:

The fundamental principle of regimen switching is to maintain viral suppression without jeopardizing future treatment options. The reasons to consider regimen switching in the viral suppressed population are to simplify the regimen by reducing the pill burden and dosing frequency, to increase the tolerability, reduce the adverse effects as well as long-term toxicities, to prevent drug-to-drug interactions and to avoid the dietary requirements. Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a single-tablet once daily regimen, will be an affordable regimen with the potential characteristics such as reduced pill burden, less drug to drug interaction and toxicities. The generic form (Mylan) is recently received the tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Whether DTG-containing regimen is a better option than protease inhibitors among resource-limited settings during the decisions for second-line treatment options, is needed to be evaluated. All participants will be switched from their pre-study ART regimen to a single tablet regimen (STR) of TAF/FTC/DTG 25/200/50mg once daily.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 170
• Est. completion date: April 4, 2023
• Est. primary completion date: April 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Documented HIV-1 infection

2. Aged =18 years old

3. Female participant may be eligible to participate if she:

is of non-childbearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea or >=54 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or, is of child-bearing potential, with a negative pregnancy test at both Screening and week 0 and agrees to use one of the protocol-defined methods of contraception to avoid pregnancy.

4. On current ART for at least 6 months prior to study entry

5. Current ART includes boosted protease inhibitors

6. No more than one HIV-1 plasma RNA >50 copies/mL and <200 copies/L (only one 'blip') in the past 6 months with a subsequent HIV-1 plasma RNA <50 copies/mL

7. HIV-1 plasma RNA <50 copies/mL at screening visit

8. No prior or current exposure to integrase strand transfer inhibitor (INSTI)

9. Have signed the informed consent form

Exclusion Criteria:

1. Breastfeeding female

2. Pregnancy or positive UPT at screening

3. Calculated creatinine clearance as estimated by Cockcroft-Gault equation (CrCl) <60 mL/min,

4. Alanine aminotransferase (ALT) >2.5 x ULN,

5. Concomitant use of any of the following medications:

(1) aluminum and magnesium-containing antacids, proton-pump inhibitors (2) anticonvulsants:

carbamazepine, oxcarbamazepine, phenobarbital, phenytoin (3) antimycobacterials: rifabutin, rifampin, rifapentine (4) St. John's wort

6. Alcohol or drug abuse that, in the opinion of the investigator, would interfere with completion of study procedures

7. Any serious illness that, in the opinion of the investigator, would interfere with completion of study procedures

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• generic single tablet TAF/FTC/DTG
HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir

Locations

Country	Name	City	State
Thailand	HIV-NAT, Thai Red Cross AIDS Research Centre	Bangkok
Thailand	Police General Hospital	Bangkok

Sponsors (4)

Lead Sponsor	Collaborator
The HIV Netherlands Australia Thailand Research Collaboration	Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University, Faculty of Medical Sciences, Radboud University of Medical Center, Police General Hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of subjects with undetectable viral load	Proportion of participants with plasma HIV-1 RNA <50 copies/mL using Snapshot algorithm at week 48	48 weeks
Secondary	Proportion of participants without tolerability failure	Proportion of participants without tolerability failure	weeks 24 and weeks 48
Secondary	Cmax of DTG	maximum plasma concentration (Cmax) of DTG 50 mg	weeks 24 and weeks 48
Secondary	Tmax of DTG	time to reach maximal concentration (Tmax) of DTG 50 mg	weeks 24 and weeks 48
Secondary	AUC of DTG	area under the curve of a plasma concentration versus time profile (AUC) of DTG 50 mg	weeks 24 and weeks 48
Secondary	T1/2 of DTG	elimination half life (T1/2) of DTG 50 mg	weeks 24 and weeks 48
Secondary	Ke of DTG	elimination rate constant (Ke) of DTG 50 mg	weeks 24 and weeks 48
Secondary	CL of DTG	total plasma clearance (CL) of DTG 50 mg	weeks 24 and weeks 48
Secondary	Anxiety at baseline will be compared to level of anxiety at weeks 24 and weeks 48.	Anxiety at baseline will be compared to anxiety level at weeks 24 and weeks 48. Anxiety will be assessed using Hospital Anxiety and Depression Scale (HADS). There are 7 different items that assess the level of anxiety of the participants based on a four-point grading scale specific for each item assessed (i.e., I feel tense or 'wound up'; 0 = not at all; 1 = from time to time, occasionally; 2 = a lot of the time; 3 = most of the time). If the total score is between 0-7, then this is considered to be normal. If the total score is between 8-10, then this is considered borderline abnormal (borderline case). If the total score is between 11-21, then this is considered abnormal (case).	weeks 24 and weeks 48
Secondary	Depression at baseline will be compared to depression level at weeks 24 and weeks 48.	Depression at baseline will be compared to depression level at weeks 24 and weeks 48. Depression will be assessed using Hospital Anxiety and Depression Scale (HADS). There are 7 different items that assess the level of depression of the participants based on a four-point grading scale specific for each item assessed (i.e., I still enjoy the things I used to enjoy; 0 = definitely as much; 1 = not quite so much; 2 = only a little; 3 = hardly at all). If the total score is between 0-7, then this is considered to be normal. If the total score is between 8-10, then this is considered borderline abnormal (borderline case). If the total score is between 11-21, then this is considered abnormal (case).	weeks 24 and weeks 48
Secondary	Changes from baseline in fasting lipid profiles	Changes from baseline in fasting lipid profiles (HDL, LDL, cholesterol, TG)	weeks 24 and weeks 48
Secondary	Changes from baseline in insulin	Changes from baseline in insulin	weeks 24 and weeks 48
Secondary	Changes from baseline in fasting blood glucose levels	Changes from baseline in fasting blood glucose levels	weeks 24 and weeks 48
Secondary	Changes from baseline in renal parameters (creatinine, eGFR)	Changes from baseline in renal parameters (creatinine, eGFR)	weeks 24 and weeks 48
Secondary	Changes from baseline in transient elastography results	Changes from baseline in transient elastography results	weeks 24 and weeks 48